Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Peripheral Nervous System Diseases 5 Lymphoma 5 Head and Neck Neoplasms 4 Breast Neoplasms 4 Neoplasms 3 Lymphoma, Large B-Cell, Diffuse 3 Colorectal Neoplasms 3 Stomatitis 2 Stomach Neoplasms 2 Sarcoma 2 Pain 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Neoplasm Metastasis 2 Multiple Myeloma 2 Mucositis 2 Malnutrition 2 Wilms Tumor 1 Vaso-Occlusive Crises 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcopenia 1 Recurrence 1 Radiation Injuries 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Oral Complications 1 Neurotoxicity Syndromes 1 Neoplasms, Plasma Cell 1 Multiple Endocrine Neoplasia Type 1 1 Malignant mesenchymal tumor 1

Interventions

Sirolimus 10 Everolimus 6 Imatinib Mesylate 2 temsirolimus 1 saracatinib 1 nintedanib 1 carbon-11 acetate 1 Valproic Acid 1 Urination 1 Sugars 1 Simvastatin 1 Resveratrol 1 Respiratory Function Tests 1 Phlebotomy 1 Octreotide 1 Loratadine 1 Letrozole 1 Immunoglobulin G 1 Hydroxychloroquine 1 Glutamine 1 Genetic Testing 1 Doxycycline 1 Disulfides 1 Cetuximab 1 Celecoxib 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphangioleiomyomatosis × Glutamine × Clear all

NCT04388371 2021-08-11

Glutamine PET Imaging in LAM

Vanderbilt University Medical Center

Phase 1 Completed

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡